Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Cell Lines as Biological Models: Practical Steps for More Reliable Research.

Capes-Davis A, Bairoch A, Barrett T, Burnett EC, Dirks WG, Hall EM, Healy L, Kniss DA, Korch C, Liu Y, Neve RM, Nims RW, Parodi B, Schweppe RE, Storts DR, Tian F.

Chem Res Toxicol. 2019 Sep 16;32(9):1733-1736. doi: 10.1021/acs.chemrestox.9b00215. Epub 2019 Jun 15.

PMID:
31203605
2.

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.

Sperandio D, Aktoudianakis V, Babaoglu K, Chen X, Elbel K, Chin G, Corkey B, Du J, Jiang B, Kobayashi T, Mackman R, Martinez R, Yang H, Zablocki J, Kusam S, Jordan K, Webb H, Bates JG, Lad L, Mish M, Niedziela-Majka A, Metobo S, Sapre A, Hung M, Jin D, Fung W, Kan E, Eisenberg G, Larson N, Newby ZER, Lansdon E, Tay C, Neve RM, Shevick SL, Breckenridge DG.

Bioorg Med Chem. 2019 Feb 1;27(3):457-469. doi: 10.1016/j.bmc.2018.11.020. Epub 2018 Nov 15.

PMID:
30606676
3.

HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases.

Paroni G, Bolis M, Zanetti A, Ubezio P, Helin K, Staller P, Gerlach LO, Fratelli M, Neve RM, Terao M, Garattini E.

Oncogene. 2019 Apr;38(15):2675-2689. doi: 10.1038/s41388-018-0620-6. Epub 2018 Dec 11.

PMID:
30538297
4.

Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.

Yen I, Shanahan F, Merchant M, Orr C, Hunsaker T, Durk M, La H, Zhang X, Martin SE, Lin E, Chan J, Yu Y, Amin D, Neve RM, Gustafson A, Venkatanarayan A, Foster SA, Rudolph J, Klijn C, Malek S.

Cancer Cell. 2018 Oct 8;34(4):611-625.e7. doi: 10.1016/j.ccell.2018.09.002.

5.

Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.

Korch C, Hall EM, Dirks WG, Ewing M, Faries M, Varella-Garcia M, Robinson S, Storts D, Turner JA, Wang Y, Burnett EC, Healy L, Kniss D, Neve RM, Nims RW, Reid YA, Robinson WA, Capes-Davis A.

Int J Cancer. 2018 Feb 1;142(3):561-572. doi: 10.1002/ijc.31067. Epub 2017 Oct 10.

6.

The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.

Hoeflich KP, Guan J, Edgar KA, O'Brien C, Savage H, Wilson TR, Neve RM, Friedman LS, Wallin JJ.

Genes Cancer. 2016 Mar;7(3-4):73-85. doi: 10.18632/genesandcancer.100.

7.

Authentication: A Standard Problem or a Problem of Standards?

Capes-Davis A, Neve RM.

PLoS Biol. 2016 Jun 14;14(6):e1002477. doi: 10.1371/journal.pbio.1002477. eCollection 2016 Jun.

8.

Reproducible pharmacogenomic profiling of cancer cell line panels.

Haverty PM, Lin E, Tan J, Yu Y, Lam B, Lianoglou S, Neve RM, Martin S, Settleman J, Yauch RL, Bourgon R.

Nature. 2016 May 19;533(7603):333-7. doi: 10.1038/nature17987.

PMID:
27193678
9.

Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance.

Patel D, Gao Y, Son K, Siltanen C, Neve RM, Ferrara K, Revzin A.

Lab Chip. 2015 Dec 21;15(24):4614-24. doi: 10.1039/c5lc00948k. Epub 2015 Nov 6.

PMID:
26542093
10.

The culture of cell culture practices and authentication--Results from a 2015 Survey.

Freedman LP, Gibson MC, Wisman R, Ethier SP, Soule HR, Reid YA, Neve RM.

Biotechniques. 2015 Oct 1;59(4):189-90, 192. doi: 10.2144/000114344. eCollection 2015 Oct. No abstract available.

11.

Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity.

Yin Y, Djakovic S, Marsters S, Tien J, Peng J, Tremayne J, Lee G, Neve RM, Wu Y, Merchant M, Ashkenazi A, Carter PJ.

Mol Cancer Ther. 2015 Oct;14(10):2270-8. doi: 10.1158/1535-7163.MCT-14-1050. Epub 2015 Aug 12.

12.

Reproducibility: changing the policies and culture of cell line authentication.

Freedman LP, Gibson MC, Ethier SP, Soule HR, Neve RM, Reid YA.

Nat Methods. 2015 Jun;12(6):493-7. doi: 10.1038/nmeth.3403. No abstract available.

PMID:
26020501
13.

A resource for cell line authentication, annotation and quality control.

Yu M, Selvaraj SK, Liang-Chu MM, Aghajani S, Busse M, Yuan J, Lee G, Peale F, Klijn C, Bourgon R, Kaminker JS, Neve RM.

Nature. 2015 Apr 16;520(7547):307-11. doi: 10.1038/nature14397.

PMID:
25877200
14.

Human biosample authentication using the high-throughput, cost-effective SNPtrace(TM) system.

Liang-Chu MM, Yu M, Haverty PM, Koeman J, Ziegle J, Lee M, Bourgon R, Neve RM.

PLoS One. 2015 Feb 25;10(2):e0116218. doi: 10.1371/journal.pone.0116218. eCollection 2015.

15.

A comprehensive transcriptional portrait of human cancer cell lines.

Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, Pau G, Reeder J, Cao Y, Mukhyala K, Selvaraj SK, Yu M, Zynda GJ, Brauer MJ, Wu TD, Gentleman RC, Manning G, Yauch RL, Bourgon R, Stokoe D, Modrusan Z, Neve RM, de Sauvage FJ, Settleman J, Seshagiri S, Zhang Z.

Nat Biotechnol. 2015 Mar;33(3):306-12. doi: 10.1038/nbt.3080. Epub 2014 Dec 8.

PMID:
25485619
16.

AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.

Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, Ashkenazi A, Settleman J.

Cancer Res. 2014 Oct 15;74(20):5878-90. doi: 10.1158/0008-5472.CAN-14-1009. Epub 2014 Aug 14.

17.

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.

Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Gr├╝tzmann R, Romero M, Totpal K, Neve RM, Yan Y, Forrest WF, Wang Y, Raja R, Pilarsky C, de Jesus-Acosta A, Belvin M, Friedman LS, Merchant M, Jaffee EM, Zheng L, Koeppen H, Hoeflich KP.

J Pathol. 2014 Dec;234(4):502-13. doi: 10.1002/path.4412. Epub 2014 Oct 6.

18.

Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition.

Edgar KA, Crocker L, Cheng E, Wagle MC, Wongchenko M, Yan Y, Wilson TR, Dompe N, Neve RM, Belvin M, Sampath D, Friedman LS, Wallin JJ.

Genes Cancer. 2014 Mar;5(3-4):113-26.

19.

Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer.

Liu J, McCleland M, Stawiski EW, Gnad F, Mayba O, Haverty PM, Durinck S, Chen YJ, Klijn C, Jhunjhunwala S, Lawrence M, Liu H, Wan Y, Chopra V, Yaylaoglu MB, Yuan W, Ha C, Gilbert HN, Reeder J, Pau G, Stinson J, Stern HM, Manning G, Wu TD, Neve RM, de Sauvage FJ, Modrusan Z, Seshagiri S, Firestein R, Zhang Z.

Nat Commun. 2014 May 8;5:3830. doi: 10.1038/ncomms4830.

20.

Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes.

Lee GY, Haverty PM, Li L, Kljavin NM, Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, Davis D, Stokoe D, Settleman J, de Sauvage FJ, Neve RM.

Cancer Res. 2014 Jun 1;74(11):3114-26. doi: 10.1158/0008-5472.CAN-13-2683. Epub 2014 Apr 22.

21.

A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.

Bentley C, Jurinka SS, Kljavin NM, Vartanian S, Ramani SR, Gonzalez LC, Yu K, Modrusan Z, Du P, Bourgon R, Neve RM, Stokoe D.

Biochem J. 2013 Jun 1;452(2):313-20. doi: 10.1042/BJ20121578.

PMID:
23496764
22.

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.

Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, Guillory J, Bhatt D, Vartanian S, Walter K, Chan J, Holcomb T, Dijkgraaf P, Johnson S, Koeman J, Minna JD, Gazdar AF, Stern HM, Hoeflich KP, Wu TD, Settleman J, de Sauvage FJ, Gentleman RC, Neve RM, Stokoe D, Modrusan Z, Seshagiri S, Shames DS, Zhang Z.

Genome Res. 2012 Dec;22(12):2315-27. doi: 10.1101/gr.140988.112. Epub 2012 Oct 2.

23.

Integrating biological knowledge into variable selection: an empirical Bayes approach with an application in cancer biology.

Hill SM, Neve RM, Bayani N, Kuo WL, Ziyad S, Spellman PT, Gray JW, Mukherjee S.

BMC Bioinformatics. 2012 May 11;13:94. doi: 10.1186/1471-2105-13-94.

24.

Subtype and pathway specific responses to anticancer compounds in breast cancer.

Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9. doi: 10.1073/pnas.1018854108. Epub 2011 Oct 14.

25.

A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers.

Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB.

Clin Proteomics. 2010 Dec;6(4):129-51. doi: 10.1007/s12014-010-9055-y.

26.

ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.

Krig SR, Miller JK, Frietze S, Beckett LA, Neve RM, Farnham PJ, Yaswen PI, Sweeney CA.

Oncogene. 2010 Oct 7;29(40):5500-10. doi: 10.1038/onc.2010.289. Epub 2010 Jul 26.

27.

Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer.

Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, Weinberg RA, Neve RM, Lenburg ME, Thompson EW.

J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):235-52. doi: 10.1007/s10911-010-9175-z. Epub 2010 Jun 4. Review.

PMID:
20521089
28.

Restriction of receptor movement alters cellular response: physical force sensing by EphA2.

Salaita K, Nair PM, Petit RS, Neve RM, Das D, Gray JW, Groves JT.

Science. 2010 Mar 12;327(5971):1380-5. doi: 10.1126/science.1181729.

29.

A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.

Kuo WL, Das D, Ziyad S, Bhattacharya S, Gibb WJ, Heiser LM, Sadanandam A, Fontenay GV, Hu Z, Wang NJ, Bayani N, Feiler HS, Neve RM, Wyrobek AJ, Spellman PT, Marton LJ, Gray JW.

BMC Med. 2009 Dec 14;7:77. doi: 10.1186/1741-7015-7-77.

30.

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.

Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT.

Clin Cancer Res. 2009 Jun 1;15(11):3654-62. doi: 10.1158/1078-0432.CCR-08-3293. Epub 2009 May 26.

31.

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM.

Cancer Res. 2009 Jan 15;69(2):565-72. doi: 10.1158/0008-5472.CAN-08-3389.

32.

Sparse combinatorial inference with an application in cancer biology.

Mukherjee S, Pelech S, Neve RM, Kuo WL, Ziyad S, Spellman PT, Gray JW, Speed TP.

Bioinformatics. 2009 Jan 15;25(2):265-71. doi: 10.1093/bioinformatics/btn611. Epub 2008 Nov 27.

33.

Unraveling the biologic and clinical complexities of HER2.

Park JW, Neve RM, Szollosi J, Benz CC.

Clin Breast Cancer. 2008 Oct;8(5):392-401. doi: 10.3816/CBC.2008.n.047. Review.

PMID:
18952552
34.

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT.

Cancer Res. 2008 Aug 1;68(15):6084-91. doi: 10.1158/0008-5472.CAN-07-6854.

35.

The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ.

Mol Oncol. 2007 Jun;1(1):84-96. doi: 10.1016/j.molonc.2007.02.004.

36.

Epithelial mesenchymal transition traits in human breast cancer cell lines.

Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, Thompson EW.

Clin Exp Metastasis. 2008;25(6):629-42. doi: 10.1007/s10585-008-9170-6. Epub 2008 May 7. Review.

PMID:
18461285
37.

Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice.

Mao JH, Wu D, Perez-Losada J, Jiang T, Li Q, Neve RM, Gray JW, Cai WW, Balmain A.

Cancer Cell. 2007 Feb;11(2):161-73.

38.

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW.

Cancer Cell. 2006 Dec;10(6):529-41.

39.

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW.

Cancer Cell. 2006 Dec;10(6):515-27.

40.

Systems biology in cancer research: genomics to cellomics.

Stilwell JL, Guan Y, Neve RM, Gray JW.

Methods Mol Biol. 2007;356:353-65.

41.

A fluid membrane-based soluble ligand-display system for live-cell assays.

Nam JM, Nair PM, Neve RM, Gray JW, Groves JT.

Chembiochem. 2006 Mar;7(3):436-40. No abstract available.

42.

Identification of an epithelial-specific enhancer regulating ESX expression.

Neve RM, Parmar H, Amend C, Chen C, Rizzino A, Benz CC.

Gene. 2006 Feb 15;367:118-25. Epub 2005 Nov 22.

PMID:
16307850
43.

A conditional feedback loop regulates Ras activity through EphA2.

Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F.

Cancer Cell. 2005 Aug;8(2):111-8.

44.
45.

A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts.

Parmar H, Young P, Emerman JT, Neve RM, Dairkee S, Cunha GR.

Endocrinology. 2002 Dec;143(12):4886-96.

PMID:
12446616
47.

ErbB2 activation of ESX gene expression.

Neve RM, Ylstra B, Chang CH, Albertson DG, Benz CC.

Oncogene. 2002 May 30;21(24):3934-8.

48.

The role of overexpressed HER2 in transformation.

Neve RM, Lane HA, Hynes NE.

Ann Oncol. 2001;12 Suppl 1:S9-13. Review.

PMID:
11521729
49.

Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.

Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC.

Biochem Biophys Res Commun. 2001 Jan 12;280(1):274-9.

PMID:
11162510
50.

The ErbB signaling network: receptor heterodimerization in development and cancer.

Olayioye MA, Neve RM, Lane HA, Hynes NE.

EMBO J. 2000 Jul 3;19(13):3159-67. Review. No abstract available.

Supplemental Content

Support Center